HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients

Nathan G. Richards, David W. Rittenhouse, Boris Freydin, Joseph A. Cozzitorto, Dane Grenda, Hallgeir Rui, Greg Gonye, Eugene P. Kennedy, Charles J. Yeo, Jonathan R. Brody, Agnieszka K. Witkiewicz

Research output: Contribution to journalArticle

75 Scopus citations

Fingerprint Dive into the research topics of 'HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients'. Together they form a unique fingerprint.

Medicine & Life Sciences